Metoprolol Tartrate and Nausea/Vomiting
Yes, metoprolol tartrate is known to cause nausea and vomiting, though these are not among its most common adverse effects. The evidence from cardiovascular guidelines and clinical trials consistently documents gastrointestinal side effects including nausea as recognized adverse events with this beta-blocker.
Evidence from Clinical Guidelines
The 2016 ACC/AHA/HRS guideline for supraventricular tachycardia explicitly lists the potential adverse effects of intravenous metoprolol tartrate, which include hypotension, worsening heart failure, bronchospasm, and bradycardia 1. While nausea is not specifically highlighted in this acute care table, the 2013 ACCF/AHA STEMI guideline provides broader context for metoprolol use in cardiovascular disease 2.
Clinical Trial Data
The most robust evidence comes from heart failure trials that systematically tracked adverse events. In the MERIT-HF trial comparing metoprolol to placebo, nausea occurred in 8.6% of patients receiving metoprolol versus 4.5% receiving placebo, representing a 4.1% absolute increase (adjusted odds ratio 1.99,95% CI 1.16-3.42, p=0.0019) 3. This represents a statistically significant and clinically meaningful increase in nausea rates.
Vomiting was also documented, occurring in 6.6% of metoprolol-treated patients compared to 5.3% in placebo patients 3. While the difference was smaller than for nausea, it demonstrates that both upper gastrointestinal symptoms can occur with metoprolol therapy.
Clinical Context and Comparison
Gastrointestinal adverse effects are generally less prominent than cardiovascular effects (hypotension, bradycardia) or respiratory effects (bronchospasm) with metoprolol 1, 2
The frequency of nausea/vomiting is lower than other common beta-blocker side effects such as fatigue (25.4% in MERIT-HF) or dizziness (12.5%) 3
These symptoms typically occur early in treatment and may improve with continued therapy or dose adjustment 4
Important Clinical Considerations
When patients on metoprolol present with nausea or vomiting, alternative etiologies must be carefully evaluated including:
- Underlying cardiac disease progression or heart failure decompensation 2
- Concurrent medications (particularly opioids, which commonly cause nausea) 5
- Gastrointestinal pathology unrelated to the medication 6
The beta-1 selectivity of metoprolol does not eliminate gastrointestinal side effects, as these are not mediated through beta-receptor blockade but likely through other mechanisms 4.
Dose-dependent effects may occur, with higher doses potentially associated with increased gastrointestinal symptoms, though systematic dose-response data for nausea specifically are limited 7, 8.